130 related articles for article (PubMed ID: 20519297)
21. Frequency and clinical consequences associated with sidebranch occlusion during stent implantation using zotarolimus-eluting and paclitaxel-eluting coronary stents.
Popma JJ; Mauri L; O'Shaughnessy C; Overlie P; McLaurin B; Almonacid A; Kirtane A; Leon MB
Circ Cardiovasc Interv; 2009 Apr; 2(2):133-9. PubMed ID: 20031706
[TBL] [Abstract][Full Text] [Related]
22. Drug-eluting or bare-metal stents for acute myocardial infarction.
Mauri L; Silbaugh TS; Garg P; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Normand SL
N Engl J Med; 2008 Sep; 359(13):1330-42. PubMed ID: 18815397
[TBL] [Abstract][Full Text] [Related]
23. Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents.
Tandjung K; Basalus MW; Muurman E; Louwerenburg HW; van Houwelingen KG; Stoel MG; de Man FH; Jansen H; Huisman J; Linssen GC; Droste HT; Nienhuis MB; von Birgelen C
Catheter Cardiovasc Interv; 2012 Oct; 80(4):524-30. PubMed ID: 22109857
[TBL] [Abstract][Full Text] [Related]
24. First human use of the TAXUS Petal paclitaxel-eluting bifurcation stent.
Ormiston JA; Lefèvre T; Grube E; Allocco DJ; Dawkins KD
EuroIntervention; 2010 May; 6(1):46-53. PubMed ID: 20542797
[TBL] [Abstract][Full Text] [Related]
25. Current status of the Xience V® everolimus-eluting coronary stent system.
Claessen BE; Caixeta A; Henriques JP; Piek JJ
Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
[TBL] [Abstract][Full Text] [Related]
26. Impact of drug-eluting stent type on periprocedural myocardial necrosis.
Wakabayashi K; Delhaye C; Mahmoudi M; Belle L; Ben-Dor I; Gaglia MA; Suddath WO; Satler LF; Kent KM; Pichard AD; Lindsay J; Waksman R
EuroIntervention; 2011 May; 7(1):136-42. PubMed ID: 21550914
[TBL] [Abstract][Full Text] [Related]
27. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions.
Pervaiz MH; Sood P; Sudhir K; Hermiller JB; Hou L; Hattori K; Su X; Cao S; Wang J; Applegate RJ; Kereiakes DJ; Yaqub M; Stone GW; Cutlip DE
Circ Cardiovasc Interv; 2012 Apr; 5(2):150-6. PubMed ID: 22438430
[TBL] [Abstract][Full Text] [Related]
28. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).
Smits PC; Kedhi E; Royaards KJ; Joesoef KS; Wassing J; Rademaker-Havinga TA; McFadden E
J Am Coll Cardiol; 2011 Jun; 58(1):11-8. PubMed ID: 21514083
[TBL] [Abstract][Full Text] [Related]
29. Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading?
Hillegass WB
Catheter Cardiovasc Interv; 2010 Jul; 76(1):58-9. PubMed ID: 20578193
[No Abstract] [Full Text] [Related]
30. The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents.
Kounis NG; Giannopoulos S; Goudevenos JA
Catheter Cardiovasc Interv; 2010 Dec; 76(7):1076-7; author reply 1078. PubMed ID: 21086494
[No Abstract] [Full Text] [Related]
31. Propensity-matched patient-level comparison of the TAXUS Liberté and TAXUS element (ION) paclitaxel-eluting stents.
Kereiakes DJ; Cannon LA; Ormiston JA; Turco MA; Mann T; Mishkel GJ; McGarry T; Wang H; Underwood P; Dawkins KD
Am J Cardiol; 2011 Sep; 108(6):828-37. PubMed ID: 21803319
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial.
Witzenbichler B; Wöhrle J; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Hood KL; Parise H; Lansky AJ; Nikolsky E; Mehran R; Stone GW
Circ Cardiovasc Interv; 2011 Apr; 4(2):130-8. PubMed ID: 21364152
[TBL] [Abstract][Full Text] [Related]
33. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial.
Guagliumi G; Costa MA; Sirbu V; Musumeci G; Bezerra HG; Suzuki N; Matiashvili A; Lortkipanidze N; Mihalcsik L; Trivisonno A; Valsecchi O; Mintz GS; Dressler O; Parise H; Maehara A; Cristea E; Lansky AJ; Mehran R; Stone GW
Circulation; 2011 Jan; 123(3):274-81. PubMed ID: 21220730
[TBL] [Abstract][Full Text] [Related]
34. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes DJ; Smits PC; Kedhi E; Parise H; Fahy M; Serruys PW; Stone GW
EuroIntervention; 2011 May; 7(1):74-83. PubMed ID: 21550906
[TBL] [Abstract][Full Text] [Related]
35. Impact of the first-generation drug-eluting stent implantation on periprocedural myocardial injury in patients with stable angina pectoris.
Okada T; Yoshikawa D; Ishii H; Matsumoto M; Hayakawa S; Matsudaira K; Tanaka M; Kumagai S; Hayashi M; Ando H; Amano T; Murohara T
J Cardiol; 2012 Oct; 60(4):264-9. PubMed ID: 22738692
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of bare metal stent implantation for patients with acute myocardial infarction in the drug-eluting stent era.
Fujimoto H; Tao S; Masuda J; Mitani H; Ito S; Fujimoto Y; Maehara A; Ishiwata S; Yamaguchi T; Ohno M
J Cardiol; 2008 Jun; 51(3):189-95. PubMed ID: 18522794
[TBL] [Abstract][Full Text] [Related]
37. More openness and a little less strut: two good ideas for stents and the people who implant them.
Morrison DA
Catheter Cardiovasc Interv; 2010 Nov; 76(5):652-3. PubMed ID: 20976746
[No Abstract] [Full Text] [Related]
38. Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating.
Soucy NV; Feygin JM; Tunstall R; Casey MA; Pennington DE; Huibregtse BA; Barry JJ
EuroIntervention; 2010 Nov; 6(5):630-7. PubMed ID: 21044918
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model.
Radeleff B; Lopez-Benitez R; Stampfl U; Stampfl S; Sommer C; Thierjung H; Berger I; Kauffmann G; Richter GM
J Vasc Interv Radiol; 2010 Aug; 21(8):1262-70. PubMed ID: 20656224
[TBL] [Abstract][Full Text] [Related]
40. Drug-eluting versus bare-metal stents in large coronary arteries.
Kaiser C; Galatius S; Erne P; Eberli F; Alber H; Rickli H; Pedrazzini G; Hornig B; Bertel O; Bonetti P; De Servi S; Brunner-La Rocca HP; Ricard I; Pfisterer M;
N Engl J Med; 2010 Dec; 363(24):2310-9. PubMed ID: 21080780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
